VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
VM Oncology, LLC
VM Oncology, LLC
Memorial Sloan Kettering Cancer Center
Incyte Corporation
NuCana plc
Medicenna Therapeutics, Inc.
Incyte Corporation